Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that the company will present clinical data from its AL001 program and preclinical data from its AL002 program at the 2019 Alzheimer’s Association International Conference (AAIC). The conference is being held July 14-18, 2019 in Los Angeles.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.